GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CVRx Inc (NAS:CVRX) » Definitions » Beneish M-Score

CVRx (CVRX) Beneish M-Score : -2.78 (As of May. 13, 2024)


View and export this data going back to 2021. Start your Free Trial

What is CVRx Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.78 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for CVRx's Beneish M-Score or its related term are showing as below:

CVRX' s Beneish M-Score Range Over the Past 10 Years
Min: -2.78   Med: -2.27   Max: -1.44
Current: -2.78

During the past 5 years, the highest Beneish M-Score of CVRx was -1.44. The lowest was -2.78. And the median was -2.27.


CVRx Beneish M-Score Historical Data

The historical data trend for CVRx's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CVRx Beneish M-Score Chart

CVRx Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
- - -1.44 -2.27 -2.78

CVRx Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.79 -2.86 -3.00 -2.78 -

Competitive Comparison of CVRx's Beneish M-Score

For the Medical Devices subindustry, CVRx's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CVRx's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, CVRx's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where CVRx's Beneish M-Score falls into.



CVRx Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of CVRx for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.7845+0.528 * 0.9247+0.404 * 1.0833+0.892 * 1.7489+0.115 * 1.1736
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.7371+4.679 * -0.052313-0.327 * 2.7734
=-2.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $7.55 Mil.
Revenue was 11.305 + 10.511 + 9.5 + 7.979 = $39.30 Mil.
Gross Profit was 9.585 + 8.82 + 7.983 + 6.651 = $33.04 Mil.
Total Current Assets was $112.09 Mil.
Total Assets was $115.23 Mil.
Property, Plant and Equipment(Net PPE) was $3.11 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.52 Mil.
Selling, General, & Admin. Expense(SGA) was $64.51 Mil.
Total Current Liabilities was $7.86 Mil.
Long-Term Debt & Capital Lease Obligation was $30.38 Mil.
Net Income was -9.163 + -9.011 + -11.651 + -11.374 = $-41.20 Mil.
Non Operating Income was 1.116 + 1.056 + 0.616 + 1.062 = $3.85 Mil.
Cash Flow from Operations was -7.839 + -8.125 + -12.808 + -10.249 = $-39.02 Mil.
Total Receivables was $5.50 Mil.
Revenue was 7.176 + 6.186 + 5.031 + 4.076 = $22.47 Mil.
Gross Profit was 5.667 + 4.846 + 3.83 + 3.127 = $17.47 Mil.
Total Current Assets was $122.88 Mil.
Total Assets was $124.94 Mil.
Property, Plant and Equipment(Net PPE) was $2.03 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.41 Mil.
Selling, General, & Admin. Expense(SGA) was $50.05 Mil.
Total Current Liabilities was $8.09 Mil.
Long-Term Debt & Capital Lease Obligation was $6.86 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(7.551 / 39.295) / (5.504 / 22.469)
=0.192162 / 0.24496
=0.7845

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(17.47 / 22.469) / (33.039 / 39.295)
=0.777516 / 0.840794
=0.9247

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (112.09 + 3.112) / 115.229) / (1 - (122.878 + 2.032) / 124.937)
=0.000234 / 0.000216
=1.0833

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=39.295 / 22.469
=1.7489

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.412 / (0.412 + 2.032)) / (0.522 / (0.522 + 3.112))
=0.168576 / 0.143643
=1.1736

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(64.509 / 39.295) / (50.045 / 22.469)
=1.641659 / 2.227291
=0.7371

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((30.382 + 7.864) / 115.229) / ((6.864 + 8.088) / 124.937)
=0.331913 / 0.119676
=2.7734

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-41.199 - 3.85 - -39.021) / 115.229
=-0.052313

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

CVRx has a M-score of -2.78 suggests that the company is unlikely to be a manipulator.


CVRx (CVRX) Business Description

Traded in Other Exchanges
N/A
Address
9201 West Broadway Avenue, Suite 650, Minneapolis, MN, USA, 55445
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
Executives
Johnson & Johnson Innovation - Jjdc, Inc. 10 percent owner 410 GEORGE STREET, NEW BRUNSWICK NJ 08901
Paul Verrastro officer: Chief Marketing Officer 9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
Kevin Hykes director 2 GOODYEAR, SUITE B, IRVINE CA 92618
Kirk G. Nielsen director ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Mudit K. Jain director C/O TREO VENTURES, 140 WASHINGTON STREET, SUITE 200, RENO NV 89503
Craig E. Palmer officer: SVP, U.S. Sales 9201 WEST BROADWAY AVENUE, SUITE 650, MINNEAPOLIS MN 55445
Martha Shadan director 9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
New Enterprise Associates 10 L P 10 percent owner
Nea Partners 10 L P 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202
Geoffrey B Pardo director 100 DOMAIN DRIVE, EXETER NH 03833
Jared Oasheim officer: Chief Financial Officer 9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
John Brintnall officer: Chief Strategy Officer and Sec 9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
Dean Bruhn-ding officer: VP of Reg. Affairs and QA 9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
Liz Galle officer: VP of Global Clinical Research 9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
Nadim Yared director, officer: Chief Executive Officer 9201 W BROADWAY AVE #650, MINNEAPOLIS MN 55445

CVRx (CVRX) Headlines

From GuruFocus

CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2022 Financial Results

By Stock market mentor Stock market mentor 01-09-2023

CVRx Inc (CVRX) Reports Q3 2023 Financial Results

By GuruFocus Research 10-26-2023

CVRx to Present at the Piper Sandler 34th Annual Healthcare Conference

By Value_Insider Value_Insider 11-16-2022

CVRx to Present at the William Blair 42nd Annual Growth Stock Conference

By GuruFocusNews GuruFocusNews 07-02-2022

CVRx Reports First Quarter 2023 Financial and Operating Results

By sperokesalga sperokesalga 04-27-2023

CVRx Launches new Barostim NEO2� Implantable Pulse Generator

By Value_Insider Value_Insider 11-03-2022

CVRx Launches a new Barostim� Programmer

By PurpleRose PurpleRose 07-12-2022